NEW YORK, NY--(Marketwire -08/29/12)- The Biotech Industry continues to be home to some of the biggest movers in the market in 2012. The anti-obesity drug market has been gaining attention among investors after the FDA approved the first weight loss drug in over a decade. The SPDR S&P Biotech ETF (XBI) has soared nearly 34 percent year-to-date. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Arena Pharmaceuticals, Inc. (ARNA) and Orexigen Therapeutics, Inc. (OREX).
Access to the full company reports can be found at:
A recent data from the European Society of Cardiology conference showed that average weight people with "fat bellies" had a higher risk of death than people who were obese. Researchers stated that people with a normal body mass index (BMI) combined with a high waist-to-hip-ratio or "central obesity" had a 2.75 time higher risk of cardiovascular death when compared to a person with normal BMI and normal waist-to-hip-ratio. The risk death from all other causes was 2.08 times higher.
"We knew from previous research that central obesity is bad, but what is new in this research is that the distribution of the fat is very important, even in people with a normal weight," said cardiologist and senior author of the study, Francisco Lopez-Jimenez. "This group has the highest death rate, even higher than those who are considered obese based on BMI."
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing oral drugs for four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The company's weight loss drug BELVIQ, recently approved by the FDA, is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain.
Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer